65,437 trials
Hemophilia A · Hemophilia B
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 33; 14; 13; 1 Participants
Mixed Hearing Loss · Single-Sided Deafness · Conductive Hearing Loss
Primary: Number of Adverse Events Quantified by Type and Severity Between Implantation and 6-months Post-surgery. — 32; 8; 3; 0 Number of events
Nutrition Disorder · Trauma · Critical Illness
Primary: Serum Concentrations of Transthyretin at 3 Weeks After Injury. — 18.1; 18.9 mg/dl
Diabetes Mellitus, Type 2
Primary: Change in Level of 13C 2-AAA in Plasma — 1.742 uM*Hr
Polymyositis · Dermatomyositis
Primary: Mean Total Improvement Score (TIS) at OLE Week 48 — 36.4 score on a scale
HIV/AIDS · Adherence, Medication · Drug Use
Primary: Acceptability of Text Messaging — 0; 0; 0; 1 Participants
Alcohol Use Disorder · Eligible to go Into the MRI Scanner · Short-term Abstinence From Alcohol Use (2 Week Abstinent)
Primary: Intervention Effects on Brain Functional Connectivity — 0.05; 0.19 percentage of Blood Oxygenation Level De
Enterocolitis, Necrotizing · Bacteremia · Bronchopulmonary Dysplasia
Primary: Number of Events of Composite Morbidities and Mortality, Including Necrotizing Enterocolitis (NEC), Late Onset Sepsis (LOS), Bronchopulmonary Dysplasia (BPD) and Death…
Peanut Allergy · Multi-food Allergy
Primary: Number of Participants by Stage 1 Treatment Assignment, Omalizumab Versus Placebo, Who Successfully Consume a Single Dose of ≥600 mg of Peanut Protein Without…
Acute Myeloid Leukemia
Primary: Survival — 35; 10; 30 percentage of patients alive for one yea
Sickle Cell Disease (SCD)
Primary: Percentage of Participants With ≥ 30% Decrease in Albuminuria (ACR) at 12 Months — 33.3; 21.4 Percentage of participants
Neovascular Age Related Macular Degeneration
Primary: Percentage Change in Choroidal Neovascularization (CNV) Lesion Area Measured by Optical Coherence Tomography-Angiograph (OCT-A) From Baseline to Week 12 — -79.29 %…
Hepatic Steatosis · Polycystic Ovarian Syndrome · Obesity
Primary: Hepatic Glucose Release — 1.85; 1.46; 1.54; 1.88 mg/kg/min
HIV Infections
Primary: PrEP Uptake — 2.764; 2.116; 2.104; 1.837 events per 1000 person-months
Hepatitis B
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Possibly or Probably Related to Treatment — 1; 1; 1; 1 Participants